Prime Medicine publishes corporate presentation on prime editing platform, liver disease pipeline focus

PRME•2026-08-06

Pipeline expansion priorities

Pipeline expansion priorities include cystic fibrosis proof-of-concept work and additional strategic partnerships to accelerate development and strengthen funding.

Progress on ex vivo CGD program

The company also flagged progress toward a BLA filing for ex vivo CGD program PM359, with a commercial launch planned for 2027+.

Prime editing platform and liver disease pipeline focus

Prime Medicine highlighted a near-term focus on in vivo liver programs, led by Wilson disease candidate PM577a and AATD candidate PM647.

PM577a received CTA and IND clearance; a Phase 1/2 trial is slated to start in H2 2026, with initial clinical data targeted in 2027.
PM647 is expected to have an IND and/or CTA filing in Q3 2026; initial clinical data is targeted in 2027.

Sources

Prime Medicine publishes corporate presentation on prime editing platform, liver disease pipeline focus

Docs

Prime Medicine publishes corporate presentation on prime editing platform, liver disease pipeline focus

Pipeline expansion priorities

Progress on ex vivo CGD program

Prime editing platform and liver disease pipeline focus

Related News

Dixie Group Q2 sales flat, profit margin edges up

Ford's new EV truck Fathom to be priced starting at about $28,000

US weekly jobless claims edge up; planned layoffs decline in July

Sources

Prime Medicine publishes corporate presentation on prime editing platform, liver disease pipeline focus

Data Storage Corp schedules Q2 2026 business update call

Aclarion Q2 FY26 net loss narrows 59.27% to $2.75 million; revenue rises 30.5% to $25,208